Aclaris Therapeutics has concluded the enrolment of 250 patients in the Phase IIb ATI-1777-AD-202 study of ATI-1777 to treat mild to severe atopic dermatitis (AD).

Aclaris is an investigational topical Janus kinase (JAK) inhibitor that is delivered as a spray-on solution to minimise systemic exposure.